NCT03744715 2024-03-05
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
Clinical Trials
4 trialsNCT02659514 2022-03-11
Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT02418689 2022-01-20
Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens
Hanmi Pharmaceutical Company Limited
Phase 2 Completed
NCT02544997 2020-07-07
A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
Samsung Medical Center
Phase 2 Completed